Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $40.78, for a total transaction of $815,600.00. Following the sale, the executive vice president directly owned 60,000 shares in the company, valued at approximately $2,446,800. The trade was a 25.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Marshall Urist also recently made the following trade(s):

• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total transaction of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Price Performance

RPRX stock opened at $40.36 on Wednesday. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $23.30 billion, a P/E ratio of 30.58, a PEG ratio of 1.93 and a beta of 0.43. The business has a 50 day simple moving average of $39.30 and a 200-day simple moving average of $37.36. Royalty Pharma PLC has a twelve month low of $29.66 and a twelve month high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.11 by $0.06. The firm had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. As a group, equities analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be issued a dividend of $0.235 per share. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s dividend payout ratio is 66.67%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on RPRX shares. TD Cowen increased their price objective on Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price objective on the stock. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Finally, Morgan Stanley lowered their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $45.60.

Key Headlines Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Company raised its quarterly dividend to $0.235, which can boost yield and appeal to income-focused investors and signals confidence in cash generation. Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235
• Positive Sentiment: Royalty struck a deal with Teva on a potential vitiligo drug, adding a new partnered asset that could generate future royalties if successful — positive for pipeline diversification and long‑term royalty upside. Teva inks deal with Royalty Pharma on potential vitiligo drug
• Positive Sentiment: Management presented a business update at the J.P. Morgan Healthcare Conference—provides transparency on deal flow, portfolio performance and near‑term catalysts that can support investor confidence. Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Full transcript of the J.P. Morgan presentation is available — useful for parsing management commentary for guidance or deal timing, but the transcript itself doesn’t change fundamentals. Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Reported short interest data appears anomalous (zeros/NaN) and likely reflects a reporting glitch rather than a substantive change in short positioning; not a clear driver of price.
• Negative Sentiment: CFO Terrance P. Coyne sold 69,582 shares (≈$2.67M) in early January, reducing his stake materially — large insider sales can be interpreted as profit‑taking or reduced insider conviction and often pressures sentiment. SEC Form 4 (Terrance P. Coyne)
• Negative Sentiment: EVP Marshall Urist sold 20,000 shares (~$815.6k) on Jan. 9, trimming his position by 25%—another sizeable insider sale that may add short‑term selling pressure. SEC Form 4 (Marshall Urist)

Institutional Investors Weigh In On Royalty Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of RPRX. Royal Bank of Canada increased its holdings in shares of Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after purchasing an additional 160,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after buying an additional 13,489 shares during the period. Focus Partners Wealth purchased a new position in Royalty Pharma in the first quarter valued at about $264,000. Intech Investment Management LLC lifted its position in shares of Royalty Pharma by 41.0% during the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 13,951 shares during the period. Finally, Strs Ohio purchased a new stake in shares of Royalty Pharma during the 1st quarter worth approximately $1,894,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.